13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This study investigated whether (18)F-FDG PET/CT performed at baseline and during neoadjuvant chemotherapy (NAC) was able to early depict estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer patients with poor clinical outcome.

          Related collections

          Author and article information

          Journal
          J. Nucl. Med.
          Journal of nuclear medicine : official publication, Society of Nuclear Medicine
          1535-5667
          0161-5505
          Jun 2015
          : 56
          : 6
          Affiliations
          [1 ] Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France dgroheux@yahoo.fr.
          [2 ] Department of Statistical Sciences, Saint-Louis Hospital, Paris, France.
          [3 ] INSERM, UMR 1101 LaTIM, Brest, France.
          [4 ] Department of Biochemistry, Saint-Louis Hospital, Paris, France.
          [5 ] Breast Diseases Unit, Department of Medical Oncology, Saint-Louis Hospital, Paris, France.
          [6 ] Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France.
          [7 ] Department of Pathology, Saint-Louis Hospital, Paris, France.
          [8 ] Department of Nuclear Medicine, CHU Bordeaux, University of Bordeaux, Bordeaux, France.
          Article
          jnumed.115.154138
          10.2967/jnumed.115.154138
          25883123
          c1d22724-7f81-4d3e-b9ce-252f1864ed4b
          © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
          History

          18FDG-PET/CT,ER+/HER2– breast cancer,SUVmax,neoadjuvant chemotherapy,prognosis,total lesion glycolysis

          Comments

          Comment on this article